371 related articles for article (PubMed ID: 30523111)
1. A mechanistic classification of clinical phenotypes in neuroblastoma.
Ackermann S; Cartolano M; Hero B; Welte A; Kahlert Y; Roderwieser A; Bartenhagen C; Walter E; Gecht J; Kerschke L; Volland R; Menon R; Heuckmann JM; Gartlgruber M; Hartlieb S; Henrich KO; Okonechnikov K; Altmüller J; Nürnberg P; Lefever S; de Wilde B; Sand F; Ikram F; Rosswog C; Fischer J; Theissen J; Hertwig F; Singhi AD; Simon T; Vogel W; Perner S; Krug B; Schmidt M; Rahmann S; Achter V; Lang U; Vokuhl C; Ortmann M; Büttner R; Eggert A; Speleman F; O'Sullivan RJ; Thomas RK; Berthold F; Vandesompele J; Schramm A; Westermann F; Schulte JH; Peifer M; Fischer M
Science; 2018 Dec; 362(6419):1165-1170. PubMed ID: 30523111
[TBL] [Abstract][Full Text] [Related]
2. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.
Koneru B; Lopez G; Farooqi A; Conkrite KL; Nguyen TH; Macha SJ; Modi A; Rokita JL; Urias E; Hindle A; Davidson H; Mccoy K; Nance J; Yazdani V; Irwin MS; Yang S; Wheeler DA; Maris JM; Diskin SJ; Reynolds CP
Cancer Res; 2020 Jun; 80(12):2663-2675. PubMed ID: 32291317
[TBL] [Abstract][Full Text] [Related]
3. Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.
Fransson S; Martinez-Monleon A; Johansson M; Sjöberg RM; Björklund C; Ljungman G; Ek T; Kogner P; Martinsson T
Sci Rep; 2020 Dec; 10(1):22432. PubMed ID: 33384420
[TBL] [Abstract][Full Text] [Related]
4. Neuroblastoma-Telomere maintenance, deregulated signaling transduction and beyond.
Stainczyk SA; Westermann F
Int J Cancer; 2022 Mar; 150(6):903-915. PubMed ID: 34636058
[TBL] [Abstract][Full Text] [Related]
5. Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma.
Yu EY; Cheung IY; Feng Y; Rabie MO; Roboz GJ; Guzman ML; Cheung NV; Lue NF
Neoplasia; 2019 Jul; 21(7):689-701. PubMed ID: 31128432
[TBL] [Abstract][Full Text] [Related]
6. Ras and Seppuku in neuroblastoma.
Reynolds CP
J Natl Cancer Inst; 2002 Mar; 94(5):319-21. PubMed ID: 11880464
[No Abstract] [Full Text] [Related]
7. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
Eleveld TF; Oldridge DA; Bernard V; Koster J; Colmet Daage L; Diskin SJ; Schild L; Bentahar NB; Bellini A; Chicard M; Lapouble E; Combaret V; Legoix-Né P; Michon J; Pugh TJ; Hart LS; Rader J; Attiyeh EF; Wei JS; Zhang S; Naranjo A; Gastier-Foster JM; Hogarty MD; Asgharzadeh S; Smith MA; Guidry Auvil JM; Watkins TB; Zwijnenburg DA; Ebus ME; van Sluis P; Hakkert A; van Wezel E; van der Schoot CE; Westerhout EM; Schulte JH; Tytgat GA; Dolman ME; Janoueix-Lerosey I; Gerhard DS; Caron HN; Delattre O; Khan J; Versteeg R; Schleiermacher G; Molenaar JJ; Maris JM
Nat Genet; 2015 Aug; 47(8):864-71. PubMed ID: 26121087
[TBL] [Abstract][Full Text] [Related]
8. Alternative lengthening of telomeres does exist in various canine sarcomas.
Kreilmeier T; Sampl S; Deloria AJ; Walter I; Reifinger M; Hauck M; Borst LB; Holzmann K; Kleiter M
Mol Carcinog; 2017 Mar; 56(3):923-935. PubMed ID: 27585244
[TBL] [Abstract][Full Text] [Related]
9. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.
Shimada H; Stram DO; Chatten J; Joshi VV; Hachitanda Y; Brodeur GM; Lukens JN; Matthay KK; Seeger RC
J Natl Cancer Inst; 1995 Oct; 87(19):1470-6. PubMed ID: 7674334
[TBL] [Abstract][Full Text] [Related]
10. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
[TBL] [Abstract][Full Text] [Related]
11. Mutations in PIK3CA are infrequent in neuroblastoma.
Dam V; Morgan BT; Mazanek P; Hogarty MD
BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308
[TBL] [Abstract][Full Text] [Related]
12. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
Sausen M; Leary RJ; Jones S; Wu J; Reynolds CP; Liu X; Blackford A; Parmigiani G; Diaz LA; Papadopoulos N; Vogelstein B; Kinzler KW; Velculescu VE; Hogarty MD
Nat Genet; 2013 Jan; 45(1):12-7. PubMed ID: 23202128
[TBL] [Abstract][Full Text] [Related]
13. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity for chromosome 14q in neuroblastoma.
Thompson PM; Seifried BA; Kyemba SK; Jensen SJ; Guo C; Maris JM; Brodeur GM; Stram DO; Seeger RC; Gerbing R; Matthay KK; Matise TC; White PS
Med Pediatr Oncol; 2001 Jan; 36(1):28-31. PubMed ID: 11464899
[TBL] [Abstract][Full Text] [Related]
15. Genetic stratification of neuroblastoma for treatment tailoring.
Jeison M; Yaniv I; Ash S
Future Oncol; 2011 Sep; 7(9):1087-99. PubMed ID: 21919696
[TBL] [Abstract][Full Text] [Related]
16. Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres.
Onitake Y; Hiyama E; Kamei N; Yamaoka H; Sueda T; Hiyama K
J Pediatr Surg; 2009 Dec; 44(12):2258-66. PubMed ID: 20006006
[TBL] [Abstract][Full Text] [Related]
17. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral diversity of telomere length in individual neuroblastoma tumors.
Pezzolo A; Pistorio A; Gambini C; Haupt R; Ferraro M; Erminio G; De Bernardi B; Garaventa A; Pistoia V
Oncotarget; 2015 Apr; 6(10):7493-503. PubMed ID: 25595889
[TBL] [Abstract][Full Text] [Related]
19. Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome.
Körber V; Stainczyk SA; Kurilov R; Henrich KO; Hero B; Brors B; Westermann F; Höfer T
Nat Genet; 2023 Apr; 55(4):619-630. PubMed ID: 36973454
[TBL] [Abstract][Full Text] [Related]
20. Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments.
Kawashima M; Kojima M; Ueda Y; Kurihara S; Hiyama E
J Pediatr Surg; 2016 Dec; 51(12):2080-2085. PubMed ID: 27793328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
